Colin Goddard

Dr. Goddard is actively involved in the Biotechnology industry as a board director and executive. He works as an investor and board member in a number of early stage and public biotechnology companies, leveraging over 30 years of experience in the industry. From October 1998, until it’s $4 billion acquisition by Astellas Pharmaceuticals, Inc. in June of 2010, Dr. Goddard was CEO of OSI Pharmaceuticals, Inc. a company he joined as a scientist in 1989. In this role he raised over $1.5 billion and oversaw the development, approval and commercial launch of Tarceva®, a leading lung cancer medicine.

He is Chairman of the board of Mission Therapeutics, and a board member at Hibercell, Inc., Ryvu Therapeutics and BlinkBio, Inc. He has been active in many organizations that support cancer research and awareness, science education and the biotechnology industry. He received his PhD in Cancer Pharmacology in the UK in1985 and conducted his postdoctoral research at the National Cancer Institute in Bethesda, MD.